Optimization of a single-chain antibody fragment overexpression in Escherichia coli using response surface methodology

Human epidermal growth factor receptor (HER) family plays an important role in various types of cancers. As a result, antibodies against HER and the mechanism of antigen-antibody binding action are under active investigation. We previously constructed a single-chain variable fragment (ScFv) against HER2, i.e. anti-Her2 ScFv, for expressing in the Escherichia coli. In the present study, we report the optimization of anti-Her2 ScFv expression in an E. coli host of BL21 (DE3) pLysS using response surface methodology based on tuning of three cultivation variables, including isopropyl-beta-D-thiogalactopyranoside (IPTG) concentration, temperature and post-induction time. A model for protein expression according to the Box-Behnken design predicted a maximal anti-Her2 ScFv expression at 37 °C, a post-induction time of 10.45 h and 0.75 mM IPTG. In addition, strategies based on inclusion body isolation and affinity chromatography were applied to purify anti-Her2 ScFv. The purity of the final product for inclusion bodies isolation and purification by Ni-NTA resin were 70 % and 95 %, respectively. The solubilization of the inclusion bodies was carried out using two denaturant agents, guanidine hydrochloride and urea. The present study showed that guanidine hydrochloride was more effective than urea in solubilizing the inclusion bodies.

[1]  G. Box,et al.  Some New Three Level Designs for the Study of Quantitative Variables , 1960 .

[2]  André I. Khuri,et al.  Response surface methodology: 1966–1988 , 1989 .

[3]  F. Studier.  Use of bacteriophage T7 lysozyme to improve an inducible T7 expression system. , 1991, Journal of molecular biology.

[4]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[5]  Douglas C. Montgomery,et al.  Response Surface Methodology: Process and Product Optimization Using Designed Experiments , 1995 .

[6]  Richard G. Brereton,et al.  Experimental design II. Optimization , 1996 .

[7]  R. H. Myers,et al.  Response Surface Methodology: Process and Product Optimization Using Designed Experiments , 1995 .

[8]  Richard G. Brereton,et al.  Experimental design 2. Optimisation , 1996 .

[9]  A. George,et al.  Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. , 1998, Journal of immunological methods.

[10]  Veronica Czitrom,et al.  One-Factor-at-a-Time versus Designed Experiments , 1999 .

[11]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[12]  M. A. Eiteman,et al.  Optimization of recombinant aminolevulinate synthase production in Escherichia coli using factorial design , 2003, Applied Microbiology and Biotechnology.

[13]  Daniel D. Frey,et al.  A role for "one-factor-at-a-time" experimentation in parameter design , 2003 .

[14]  Ville Santala,et al.  Production of a biotinylated single-chain antibody fragment in the cytoplasm of Escherichia coli. , 2004, Journal of immunological methods.

[15]  John C Joly,et al.  High‐level accumulation of a recombinant antibody fragment in the periplasm of Escherichia coli requires a triple‐mutant (degP prc spr) host strain , 2004, Biotechnology and bioengineering.

[16]  Xiao-guang Yang,et al.  Refolding and purification of non-fusion HPT protein expressed in Escherichia coli as inclusion bodies. , 2005, Protein expression and purification.

[17]  Jiju Antony,et al.  Taguchi or classical design of experiments: a perspective from a practitioner , 2006 .

[18]  Sudhir Sahdev,et al.  Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies , 2007, Molecular and Cellular Biochemistry.

[19]  S. Ferreira,et al.  Box-Behnken design: an alternative for the optimization of analytical methods. , 2007, Analytica chimica acta.

[20]  J. Zhang,et al.  Recombinant early secreted antigen target 6 protein as a skin test antigen for the specific detection of Mycobacterium tuberculosis infection , 2008, Clinical and experimental immunology.

[21]  M. Bezerra,et al.  Response surface methodology (RSM) as a tool for optimization in analytical chemistry. , 2008, Talanta.

[22]  Carl-Fredrik Mandenius,et al.  Bioprocess optimization using design‐of‐experiments methodology , 2008, Biotechnology progress.

[23]  B. Niu,et al.  [Optimization of human anti-HBsAg scFv secretary expression in Escherichia coli]. , 2009, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.

[24]  J. Hall,et al.  Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. , 2009, Biotechnology advances.

[25]  A. Nelson.  Antibody fragments , 2010, mAbs.

[26]  Elena García-Fruitós,et al.  Inclusion bodies: a new concept , 2010, Microbial cell factories.

[27]  Chen Hong,et al.  Optimization of volatile fatty acid production with co-substrate of food wastes and dewatered excess sludge using response surface methodology. , 2010, Bioresource technology.

[28]  L. Pollegioni,et al.  Optimizing HIV-1 protease production in Escherichia coli as fusion protein , 2011, Microbial cell factories.

[29]  George Georgiou,et al.  Strain engineering for improved expression of recombinant proteins in bacteria , 2011, Microbial cell factories.

[30]  S. Doglia,et al.  Concepts and tools to exploit the potential of bacterial inclusion bodies in protein science and biotechnology , 2011, The FEBS journal.

[31]  Napsiah Ismail,et al.  Workpiece surface temperature for in-process surface roughness prediction using response surface methodology , 2011 .

[32]  F. Moazen,et al.  Optimization of the expression of reteplase in Escherichia coli , 2011, Research in pharmaceutical sciences.

[33]  A. L. Larentis,et al.  Cloning and optimization of induction conditions for mature PsaA (pneumococcal surface adhesin A) expression in Escherichia coli and recombinant protein stability during long-term storage. , 2011, Protein expression and purification.

[34]  R. Jafari,et al.  Optimization of production of the anti-keratin 8 single-chain Fv TS1-218 in Pichia pastoris using design of experiments , 2011, Microbial cell factories.

[35]  Rachel Chen.  Bacterial expression systems for recombinant protein production: E. coli and beyond. , 2012, Biotechnology advances.

[36]  Robin J. Vigouroux,et al.  In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments , 2013 .

[37]  S. Dübel,et al.  Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEX™ bioreactor. , 2013, Journal of biotechnology.

[38]  W. Hittelman,et al.  Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies , 2014, Oncogene.

[39]  D. Abedi,et al.  Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli , 2014, Journal of Industrial Microbiology & Biotechnology.